BMY
Bristol-Myers Squibb Company (BMY) reported net income of $7.05B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $7.05B | +178.8% |
| FY 2024 | -$8.95B | -211.5% |
| FY 2023 | $8.03B | +26.8% |
| FY 2022 | $6.33B | -9.5% |
| FY 2021 | $6.99B | +177.6% |
| FY 2020 | -$9.02B | -362.1% |
| FY 2019 | $3.44B | -30.1% |
| FY 2018 | $4.92B | +388.6% |
| FY 2017 |
Bristol-Myers Squibb Company (BMY) reported net income of $7.05B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Bristol-Myers Squibb Company's net income grew from $3.71B to $7.05B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.01B |
| -77.4% |
| FY 2016 | $4.46B | +184.8% |
| FY 2015 | $1.56B | -21.9% |
| FY 2014 | $2.00B | -21.8% |
| FY 2013 | $2.56B | +30.8% |
| FY 2012 | $1.96B | -47.2% |
| FY 2011 | $3.71B | - |